In genetics, the term “penetrance” means an average across a population of the frequency of association of one or more particular gene mutations with a specific phenotype, e.g., autism. Many “syndromic” or “genetic” forms of autism have variable penetrance, sometimes only a few fold times more than the rates seen in the general population, and sometimes up to ~100% penetrance (e.g., genes like CHD8 and ADNP).

The higher the penetrance, the fewer the variables that are likely involved in causing the phenotype of interest. The lower the penetrance, the better the likelihood that other genes and/or environmental agencies are also playing vitally important roles. Penetrance, expressed as a percentage, gives a good idea as to the complexity of a phenotype’s etiology.
For instance, exposure to valproic acid in utero predisposes toward autistic symptomology; however, the rates of co-occurrence of Fetal Valproate Syndrome and autism are roughly 10%, which suggests a more complex picture than, say, Angelman Syndrome, in which about 80% of individuals display autistic symptomology.
The fact that rare mutations account for only a minority of cases thus far suggests a few things:
-
- Common gene variants may play small but significant roles in predisposition (e.g., the MET receptor); these are unfortunately much more challenging to identify due to the need to study such large numbers of people, sometimes numbering in the hundreds of thousands, in order to gain enough statistical power.
- Vulnerability may be polygenic (multiple common variants in conjunction).
- Environmental agencies probably also play some significant roles in determining autistic phenotype, which will vary on a case-by-case basis.
As a word of caution, when we’re talking about gene mutations associated with autism, the vast majority of those identified are the rare ones.
Why? Because it’s possible to identify those very easily. When a mutation shows up a few times in your experimental group and none of the time in the controls (and you have a large enough N), that’s likely to be a rare mutation, defined as occurring in less than 1% of the population. We know of a few common variants associated with autism, but these are few and far between. So it isn’t that genetics only explains 18-20% of the cases of autism, it’s that rare mutations primarily account for that proportion of cases. There is still much work to be done to potentially identify common variants and combinations thereof that could predispose toward autism as well. The one-fifth is only part of the story.
by Manuel Casanova, M.D. and Emily Casanova, Ph.D., University of South Carolina, Greenville, South Carolina
This editorial appears in the Autism Research Review International, Vol. 29, No. 3, 2015
Learn More
Gene Therapy for Mutations in the IQSEC2 Gene
The IQSEC2 protein is a guanine nucleotide exchange factor for Arf6. Pathogenic variants in the X-linked IQSEC2 gene are associated with drug-resistant epilepsy, severe intellectual disability, and autism. The vast
Towards the Development of a Diagnostic Test for Autism Spectrum Disorder: Data Science Meets Metabolomics
Hear Juergen Hahn, Ph.D., ARI Scientific Advisory Board member, discuss how using machine learning can lead to biomarker discoveries in autism research. Handouts are online HERE
How Genetics is Shaping the Field of Autism Research
Learn about how research on genetic influences is shaping our understanding of autism. About the speaker: M. Pilar Trelles, MD, is a licensed and
Breakthroughs in Understanding roles of Genes and Environment in Autism
About the speaker: Dr. Jonathan Sebat, Director, Beyster Center for Psychiatric Genomics Dr. Sebat leads an interdisciplinary team in the clinical and genomic analysis of
The Low-Hanging Fruit: Exploring Monogenic Syndromes with Elevated Rates of Autism
Dr. Daniel Vogt, Ph.D., explores monogenic syndromes and what they can tell us about the underlying causes of autism. He describes signaling pathways critical in early development, highlighting the electrical nature of
Biomarkers start telling us a story: Autism pathophysiology revisited
This is a joint presentation with the World Autism Organisation. Antonio Persico, MD, a recent ARI Research Grant recipient, explores the role of biomarkers in understanding autism pathophysiology. He



